

Table SI. Baseline characteristics of patients in the excluded group and included group.

Characteristic	Excluded group (n=1,073)	Included group (n=1,073)	P-value
Age, years ^a	42.26±12.11	42.34±12.32	0.552
Sex, n (%)			0.426
Male	319 (29.7%)	336 (31.3%)	
Female	754 (70.3%)	737 (68.7%)	
HT, n (%)			0.912
No	875 (81.5%)	873 (81.4%)	
Yes	198 (18.5%)	200 (18.6%)	
Subtypes, n (%)			0.939
Classic	901 (84.0%)	895 (83.4%)	
FV	131 (12.2%)	136 (12.7%)	
TCV	41 (3.8%)	42 (3.9%)	
Multifocality, n (%)			0.965
No	453 (42.2%)	454 (42.3%)	
Yes	620 (57.8%)	619 (57.7%)	
Tumor size, cm ^b	1.1 (0.7-1.8)	1.1 (0.7-1.8)	0.416
Capsule invasion, n (%)			0.760
No	454 (42.3%)	461 (43.0%)	
Yes	619 (57.7%)	612 (57.0%)	
Extrathyroidal invasion, n (%)			0.795
No	508 (47.3%)	514 (47.9%)	
Yes	565 (52.7%)	559 (52.1%)	
T stage, n (%)			0.995
Tx	35 (3.3%)	36 (3.4%)	
T1	616 (57.4%)	620 (57.8%)	
T2	120 (11.2%)	123 (11.5%)	
T3	235 (21.9%)	227 (21.2%)	
T4	67 (6.2%)	67 (6.2%)	
N stage, n (%)			0.927
Nx/N0	72 (6.7%)	70 (6.5%)	
N1a	487 (45.4%)	496 (46.2%)	
N1b	514 (47.9%)	507 (47.3%)	
LNR, n (%)			0.517
<5	541 (50.4%)	526 (49.0%)	
≥5	532 (49.6%)	547 (51.0%)	
M stage, n (%)			0.599
M0	979 (91.2%)	972 (90.6%)	
M1	94 (8.8%)	101 (9.4%)	
TgAb level, TgAb(+), kIU/l	26.85 (10.7,87.7)	27.0 (10.8,93.3)	0.896
Tg level, TgAb(-), µg/l	3.08 (0.9,9.2)	3.26 (1.0,9.7)	0.654
6-month response, n (%)			0.396
ER + IDR	815 (76.0%)	798 (74.4%)	
BIR + SIR	258 (24.0%)	275 (25.6%)	
3-years response, n (%)			0.385

ER + IDR	929 (86.6%)	915 (85.3%)	
BIR + SIR	144 (13.4%)	158 (14.7%)	

^aData are presented as mean \pm SD; ^bdata are presented as median (interquartile range). FV, follicular variant; TCV, tall cell variant; HT, Hashimoto's thyroiditis; T, primary tumor; N, regional lymph nodes; M, metastasis; LNR, lymph node metastasis ratio; TSH, thyroid-stimulating hormone; TgAb, thyroglobulin antibody; ER, excellent response; IDR, indeterminate response; BIR, biochemical incomplete response; SIR, structural incomplete response; SD, standard deviation.

Table SII. Univariate logistic regression analysis of factors associated with treatment response in patients with papillary thyroid carcinoma after radioactive iodine therapy.

Variable	B	OR	95% CI		P-value
			Lower	Upper	
A, 6-month response					
Age	-0.020	0.978	0.965	0.992	0.020
Sex (female)	-0.740	0.477	0.334	0.681	<0.001
HT (Yes)	-0.557	0.573	0.350	0.936	0.026
Subtypes (FV)	1.381	3.979	2.541	6.230	<0.001
Subtypes (TCV)	2.575	13.138	5.424	1.822	<0.001
Tumor size	0.522	1.685	1.426	0.990	<0.001
N stage (Nx/N0)	-0.856	0.425	0.220	0.822	0.011
LNR	0.494	1.638	1.164	0.304	0.005
M stage (M1)	3.566	35.375	16.467	5.992	<0.001
Tg level	0.062	1.064	1.048	0.080	<0.001
B, 3-year response					
Variable	B	OR	95% CI		P-value
			Lower	Upper	
Sex (female)	-0.496	0.609	0.395	0.939	0.025
Subtypes (FV)	2.201	9.035	5.476	4.906	<0.001
Subtypes (TCV)	3.044	20.979	9.095	8.389	<0.001
Tumor size	0.491	1.635	1.362	0.963	<0.001
N stage (Nx/N0)	-0.900	0.407	0.185	0.892	0.025
LNR	0.781	2.183	1.418	0.362	<0.001
M stage (M1)	4.996	147.879	60.576	61.005	<0.001
Tg level	0.120	1.127	1.101	0.154	<0.001

OR, odds ratio; CI, confidence interval; FV, follicular variant; TCV, tall cell variant; N, regional lymph nodes; M, metastasis; LNR, lymph node metastasis ratio; Tg, thyroglobulin.